RT Journal Article
SR Electronic
T1 Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.28.20029272
DO 10.1101/2020.02.28.20029272
A1 Nishiura, Hiroshi
A1 Oshitani, Hitoshi
A1 Kobayashi, Tetsuro
A1 Saito, Tomoya
A1 Sunagawa, Tomimasa
A1 Matsui, Tamano
A1 Wakita, Takaji
A1 MHLW COVID-19 Response Team
A1 Suzuki, Motoi
YR 2020
UL http://medrxiv.org/content/early/2020/03/03/2020.02.28.20029272.abstract
AB Commissioned by the Minister of the Ministry of Health, Labour, and Welfare of Japan, we collected secondary transmission data with the aim of identifying high risk transmission settings. We show that closed environments contribute to secondary transmission of COVID-19 and promote superspreading events. Closed environments are consistent with large-scale COVID-19 transmission events such as that of the ski chalet-associated cluster in France and the church- and hospital-associated clusters in South Korea. Our findings are also consistent with the declining incidence of COVID-19 cases in China, as gathering in closed environments was prohibited in the wake of the rapid spread of the disease. Reduction of unnecessary close contact in closed environments may help prevent large case clusters and superspreading events.Competing Interest StatementThe authors have declared no competing interest.Funding StatementH.N. received funding from the Japan Agency for Medical Research and Development (AMED) [grant number: JP18fk0108050]; the Japan Society for the Promotion of Science (JSPS) KAKENHI [grant numbers, H.N.: 17H04701, 17H05808, 18H04895 and 19H01074], the Inamori Foundation, and the Japan Science and Technology Agency (JST) CREST program [grant number: JPMJCR1413].Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized dataset will be provided by the corresponding author upon request.